Kronos Bio, Inc. - Common Stock (NQ:KRON)

0.8800 UNCHANGED

Last Price Updated: 9:38 AM EDT, Jun 20, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kronos Bio, Inc. - Common Stock

< Previous 1 2 3 4 Next >

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 05, 2025

Via Benzinga

Which stocks are gapping on Thursday? ↗

June 05, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

These stocks are moving in today's pre-market session ↗

June 05, 2025

Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 05, 2025

Via Benzinga

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders

May 18, 2025

From Halper Sadeh LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders

May 15, 2025

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (Nasdaq - XAGE), Southern States Bancshares, Inc. (Nasdaq

May 15, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

In today's session, these stocks are experiencing unusual volume. ↗

May 06, 2025

In today's session, these stocks are experiencing unusual volume.

Via Chartmill

KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON

May 04, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNB, COLB, KRON on Behalf of Shareholders

May 03, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Here are the top movers in Thursday's session. ↗

May 01, 2025

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Via Chartmill

Top stock movements in today's session. ↗

May 01, 2025

Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 01, 2025

Via Benzinga

The market is filled with gapping stocks in Thursday's session. ↗

May 01, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.

Via Chartmill

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP), Pacific Premier Bancorp, Inc.

May 01, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders

May 01, 2025

From Ademi & Fruchter LLP

Via Business Wire

KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders

May 01, 2025

From Halper Sadeh LLC

Via Business Wire

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

May 01, 2025

From Kronos Bio, Inc.

Via GlobeNewswire

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

March 18, 2025

From Kronos Bio, Inc.

Via GlobeNewswire

Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul ↗

November 27, 2024

Kronos Bio announces major leadership changes and an 83% workforce reduction as part of a strategic overhaul, with stock gaining in premarket.

Via Benzinga

Kronos Bio Announces CEO Transition and Reduction in Force

November 27, 2024

From Kronos Bio, Inc.

Via GlobeNewswire

Deal Dispatch: Starbucks Considers China Sale, Private Equity Bankrupts Snack Company, Darwin Financial Talks Mining ↗

November 22, 2024

Darwin Financial's Joshua Robinson talks to Benzinga about the firm's latest commodities deal, and more M&A news from this past week.

Via Benzinga

Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul ↗

November 17, 2024

Evolent Health, Kronos Bio, Saint-Gobain, Shell and Unilever are on the sell-side this week. Benzinga's Deal Dispatch has the latest M&A updates.

Via Benzinga

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

November 14, 2024

From Kronos Bio, Inc.

Via GlobeNewswire

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

November 13, 2024

From Kronos Bio, Inc.

Via GlobeNewswire

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

November 05, 2024

From Kronos Bio, Inc.

Via GlobeNewswire

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

October 23, 2024

– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity –

From Kronos Bio, Inc.

Via GlobeNewswire

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

October 09, 2024

From Kronos Bio, Inc.

Via GlobeNewswire

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease

October 07, 2024

From Kronos Bio, Inc.

Via GlobeNewswire

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

September 25, 2024

From Kronos Bio, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.